Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Lifecare AS ( (DE:LFC0) ) is now available.
Lifecare ASA has been recognised by the European Commission’s Innovation Radar as a Key Innovator for two technologies developed within the EU-funded FORGETDIABETES project. The highlighted innovations are an osmotic pressure-based implantable intra-peritoneal sensor for continuous glucose monitoring and a method to stabilise Concanavalin A, improving temperature stability and long-term sensor performance.
The recognition underscores the core role of these technologies in Lifecare’s proprietary CGM platform and their potential relevance for future standardisation activities in glucose monitoring. Publication on the Innovation Radar bolsters Lifecare’s scientific credibility as it advances its implantable CGM system toward clinical evaluation, signalling growing institutional support for novel approaches to diabetes care and long-duration glucose monitoring.
More about Lifecare AS
Lifecare ASA is a Norwegian MedTech and medical sensor company focused on next-generation Continuous Glucose Monitoring systems. The company develops implantable osmotic pressure-based sensor technology designed to monitor various analytes and molecules in humans and pets, with a primary market focus on improving glucose monitoring and diabetes management.
Average Trading Volume: 2,967,179
Current Market Cap: NOK68.4M
See more insights into LFC0 stock on TipRanks’ Stock Analysis page.